Novel methylated biomarkers and a robust assay to detect circulating tumor dna in metastatic breast cancer

Cancer Research

Volumn 74, Issue 8, 2014, Pages 2160-2170

  Fackler, Mary Jo ^a   Bujanda, Zoila Lopez ^a   Umbricht, Christopher ^a   Teo, Wei Wen ^a   Cho, Soonweng ^a   Zhang, Zhe ^a   Visvanathan, Kala ^a,b   Jeter, Stacie ^a   Argani, Pedram ^a   Wang, Chenguang ^a   Lyman, Jaclyn P ^c   De Brot, Marina ^c   Ingle, James N ^d   Boughey, Judy ^d   McGuire, Kandace ^e   King, Tari A ^c   Carey, Lisa A ^f   Cope, Leslie ^a   Wolff, Antonio C ^a   Sukumar, Saraswati ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AUTOPSY; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISTANT METASTASIS; DNA EXTRACTION; DNA METHYLATION; FEMALE; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; MARKER GENE; MULTIPLEX POLYMERASE CHAIN REACTION; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR GENE; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899550486     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3392     Document Type: Article

References (32)

1. Van De Voorde L, Speeckaert R, Van Gestel D, Bracke M, De Neve W, Delanghe J, et al. DNA methylation-based biomarkers in serum of patients with breast cancer. Mutat Res 2012;751:304-25.
2. MullerHM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 2003;63:7641-5.
3. Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 2005;65:1141-5.
4. Fiegl H, Jones A, Hauser-Kronberger C, Hutarew G, Reitsamer R, Jones RL, et al. Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. Clin Cancer Res 2008;14:3494-502.
5. Shivapurkar N, Gazdar AF. DNA methylation based biomarkers in noninvasive cancer screening. Curr Mol Med 2010;10:123-32.
6. Euhus DM, Bu D, Ashfaq R, Xie XJ, Bian A, Leitch AM, et al. Atypia and DNA methylation in nipple duct lavage in relation to predicted breast cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16: 1812-21.
7. Locke I, Kote-Jarai Z, Fackler MJ, Bancroft E, Osin P, Nerurkar A, et al. Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls. Breast Cancer Res 2007;9:R20.
8. Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, Kim JH, et al. Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch 2011;458:73-84.
9. Suijkerbuijk KP, van der Wall E, Vooijs M, van Diest PJ. Molecular analysis of nipple fluid for breast cancer screening. Pathobiology 2008;75:149-52.
10. Fackler MJ, Rivers A, Teo WW, Mangat A, Taylor E, Zhang Z, et al. Hypermethylated genes as biomarkers of cancer in women with pathologic nipple discharge. Clin Cancer Res 2009;15:3802-11.
11. Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, Merino VF, et al. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 2011;71:6195-207.
12. Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, et al. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treat 2011;127:153-62.
13. Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003;107:970-5.
14. Lee JS, Fackler MJ, Lee JH, Choi C, Park MH, Yoon JH, et al. Basal-like breast cancer displays distinct patterns of promoter methylation. Cancer Biol Ther 2010;9:1017-24.
15. Rudek MA, Connolly RM, Hoskins JM, Garrett-Mayer E, Jeter SC, Armstrong DK, et al. Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Res Treat 2013;139:135-43.
16. Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW, et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 2008; 14:1938-46.
17. Fatouros IG, Destouni A, Margonis K, Jamurtas AZ, Vrettou C, Kouretas D, et al. Cell-free plasma DNA as a novel marker of aseptic inflammation severity related to exercise overtraining. ClinChem 2006; 52:1820-4.
18. Breitbach S, Tug S, Simon P. Circulating cell-free DNA: an up-coming molecular marker in exercise physiology. Sports Med 2012;42:565-86.
19. Lo YM, Rainer TH, Chan LY, Hjelm NM, Cocks RA. Plasma DNA as a prognostic marker in trauma patients. Clin Chem 2000;46:319-23.
20. Szpechcinski A, Chorostowska-Wynimko J, Kupis W, Maszkowska- Kopij K, Dancewicz M, Kowalewski J, et al. Quantitative analysis of free-circulating DNA in plasma of patients with resectable NSCLC. Expert Opin Biol Ther. 2012;12:S3-9.
21. Rhodes A, Wort SJ, Thomas H, Collinson P, Bennett ED. Plasma DNA concentration as a predictor of mortality and sepsis in critically ill patients. Crit Care 2006;10:R60.
22. Liggett T, Melnikov A, Tilwalli S, Yi Q, Chen H, Replogle C, et al. Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci 2010;290:16-21.
23. Raptis L, Menard HA. Quantitation and characterization of plasmaDNA in normals and patients with systemic lupus erythematosus. J Clin Invest 1980;66:1391-9.
24. Beyer C, Pisetsky DS. The role of microparticles in the pathogenesis of rheumatic diseases. Nat Rev Rheumatol 2010;6:21-9.
25. Muller HM, Ivarsson L, Schrocksnadel H, Fiegl H, Widschwendter A, Goebel G, et al. DNA methylation changes in sera of women in early pregnancy are similar to those in advanced breast cancer patients. Clin Chem 2004;50:1065-8.
26. Tsui NB, Lo YM. Recent advances in the analysis of fetal nucleic acids in maternal plasma. Curr Opin Hematol 2012;19:462-8.
27. Shen J, Wang S, Zhang YJ, Kappil MA, Chen Wu H, Kibriya MG, et al. Genome-wide aberrant DNA methylation of microRNA host genes in hepatocellular carcinoma. Epigenetics 2012;7:1230-7.
28. Chan DW, Beveridge RA, Muss H, Fritsche HA, Hortobagyi G, Theriault R, et al. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 1997;15:2322-8.
29. Pedersen AC, Sorensen PD, Jacobsen EH, Madsen JS, Brandslund I. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer. Clin Chem Lab Med 2013;51:1511-9.
30. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.
31. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199-209.
32. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012; 4:136ra68.